Charles River Laboratories International (NYSE:CRL) Coverage Initiated by Analysts at Barclays

Barclays assumed coverage on shares of Charles River Laboratories International (NYSE:CRL) in a research report sent to investors on Friday morning, Benzinga reports. The firm issued an equal weight rating and a $230.00 price target on the medical research company’s stock.

A number of other research analysts have also issued reports on the company. The Goldman Sachs Group began coverage on Charles River Laboratories International in a research report on Thursday, June 6th. They set a buy rating and a $290.00 price objective for the company. TheStreet upgraded Charles River Laboratories International from a c+ rating to a b- rating in a research report on Friday, March 1st. Argus reaffirmed a hold rating on shares of Charles River Laboratories International in a research note on Friday. Mizuho started coverage on Charles River Laboratories International in a research note on Friday, June 7th. They set a neutral rating and a $235.00 target price on the stock. Finally, TD Cowen cut their target price on Charles River Laboratories International from $260.00 to $228.00 and set a hold rating on the stock in a research note on Monday, May 13th. Eight investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of Hold and a consensus target price of $254.50.

Charles River Laboratories International Trading Down 0.4 %

NYSE:CRL opened at $206.51 on Friday. Charles River Laboratories International has a 12-month low of $161.65 and a 12-month high of $275.00. The firm has a market capitalization of $10.64 billion, a P/E ratio of 24.30, a P/E/G ratio of 1.96 and a beta of 1.40. The company has a debt-to-equity ratio of 0.73, a current ratio of 1.75 and a quick ratio of 1.37. The business has a 50 day simple moving average of $220.16 and a 200 day simple moving average of $232.48.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings data on Thursday, May 9th. The medical research company reported $2.27 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.05 by $0.22. Charles River Laboratories International had a return on equity of 15.16% and a net margin of 10.81%. The business had revenue of $1.01 billion during the quarter, compared to analyst estimates of $997.24 million. Equities research analysts predict that Charles River Laboratories International will post 11 EPS for the current year.

Insider Transactions at Charles River Laboratories International

In other news, EVP Joseph W. Laplume sold 1,304 shares of the business’s stock in a transaction on Friday, May 10th. The stock was sold at an average price of $226.97, for a total value of $295,968.88. Following the sale, the executive vice president now owns 23,276 shares of the company’s stock, valued at approximately $5,282,953.72. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 1.30% of the company’s stock.

Institutional Trading of Charles River Laboratories International

Several large investors have recently made changes to their positions in the stock. American Trust bought a new stake in shares of Charles River Laboratories International during the 1st quarter worth about $250,000. Cetera Advisors LLC boosted its stake in shares of Charles River Laboratories International by 197.1% during the 1st quarter. Cetera Advisors LLC now owns 3,357 shares of the medical research company’s stock worth $910,000 after acquiring an additional 2,227 shares in the last quarter. Cetera Investment Advisers boosted its stake in shares of Charles River Laboratories International by 223.4% during the 1st quarter. Cetera Investment Advisers now owns 9,740 shares of the medical research company’s stock worth $2,639,000 after acquiring an additional 6,728 shares in the last quarter. Atria Investments Inc boosted its stake in shares of Charles River Laboratories International by 19.6% during the 1st quarter. Atria Investments Inc now owns 17,502 shares of the medical research company’s stock worth $4,742,000 after acquiring an additional 2,873 shares in the last quarter. Finally, Sanibel Captiva Trust Company Inc. boosted its stake in shares of Charles River Laboratories International by 64.7% during the 1st quarter. Sanibel Captiva Trust Company Inc. now owns 30,490 shares of the medical research company’s stock worth $8,261,000 after acquiring an additional 11,974 shares in the last quarter. Institutional investors own 98.91% of the company’s stock.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).